Trial Profile
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2023
Price :
$35
*
At a glance
- Drugs Reproxalap (Primary)
- Indications Sjogren-Larsson syndrome
- Focus Registrational; Therapeutic Use
- Acronyms RESET
- Sponsors Aldeyra Therapeutics
- 12 Mar 2020 According to an Aldeyra Therapeutics media release, the company has elected to clinical development of topical dermal reproxalap for the treatment of ichthyosis associated with Sjogren-Larsson Syndrome. This initiative prioritize Aldeyra ocular portfolio.
- 12 Mar 2020 Status changed from recruiting to suspended, according to an Aldeyra Therapeutics media release.
- 08 Aug 2019 Results presented in the Aldeyra Therapeutics financial media release.